Company Overview
Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two segments, Surgical Glaucoma and Dry Eye. It offers OMNI, a surgical system family of products, such as OMNI Ergo for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and OMNI EDGE, an implant-free and minimally invasive glaucoma surgery technology. The company also provides SION, a bladeless and manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork; and TearCare system, a proprietary, interventional, dry eye device designed to melt and facilitate the comprehensive removal of meibomian gland obstructions and restore gland functionality and healthy oil production for adult patients with evaporative dry eye disease due to meibomian gland disease when used in conjunction with manual expression of the meibomian glands for ophthalmologists and optometrists. It serves hospitals, medical centers, and eyecare professionals through sales representatives and distributors. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Why Investors Should Care
Revenue has grown at a 22.9% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $77.36M (-3.1% YoY); net profit $-38.43M.
- Trailing 12 Months Year-on-year growth — revenue +19.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 22.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 22.86% |
| 1 Year: | 19.50% |
Stock Price Performance
| 1 Year: | +96.47% |
| 6 Months: | +125.07% |
| 3 Months: | +87.64% |
| 1 Month: | +17.77% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)66.31 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 22.9% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SGHT Sight Sciences, Inc. R2KPHARMA | 8.35 | -15.18 | $459.98M | 0.00% | -35.58% | -48.42% | 22.86% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 3.50M | 8.65M | 8.63M | 12.54M | 13.10M | 14.88M | 17.23M | 18.68M | 18.82M | 23.47M | 20.01M | 19.27M | 21.37M | 20.16M | 17.51M | 19.56M | 19.91M | 19.70M | 23.39M |
| Gross Profit | - | 1.42M | 6.03M | 6.33M | 10.23M | 11.04M | 11.85M | 14.49M | 15.75M | 15.78M | 20.09M | 17.33M | 16.47M | 18.34M | 16.91M | 15.09M | 16.59M | 17.20M | 16.98M | 21.37M |
| Operating Income | - | -7.69M | -7.36M | -11.66M | -11.08M | -14.03M | -22.19M | -22.86M | -21.84M | -17.57M | -15.19M | -13.41M | -14.72M | -12.65M | -11.23M | -13.86M | -11.67M | -7.91M | -12.41M | -3.89M |
| Net Income | -9.18M | -8.32M | -8.10M | -12.24M | -17.61M | -17.17M | -23.26M | -23.84M | -22.23M | -17.07M | -14.75M | -13.04M | -16.27M | -12.33M | -11.07M | -14.15M | -11.94M | -8.17M | -12.98M | -4.45M |
| Diluted EPS | - | - | - | - | - | -0.43 | -0.49 | -0.50 | -0.46 | -0.35 | -0.30 | -0.27 | -0.33 | -0.25 | -0.22 | -0.28 | -0.23 | -0.16 | -0.24 | -0.08 |
| R&D Expense | - | 1.44M | 2.16M | 3.44M | 3.55M | 4.28M | 5.65M | 5.93M | 6.05M | 4.67M | 5.22M | 4.24M | 4.64M | 4.32M | 4.75M | 4.43M | 4.39M | 3.35M | 2.55M | 2.51M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 27.64M | 48.96M | 71.33M | 81.06M | 79.87M | 77.36M |
| Gross Profit | 18.43M | 40.35M | 58.97M | 69.17M | 68.28M | 66.67M |
| Operating Income | -32.19M | -51.48M | -83.95M | -57.27M | -50.53M | -37.10M |
| Net Income | -34.69M | -62.96M | -86.24M | -55.55M | -51.51M | -38.43M |
| Diluted EPS | - | -2.36 | -1.80 | -1.14 | -1.03 | -0.74 |
| R&D Expense | 8.87M | 15.63M | 22.86M | 17.56M | 17.99M | 14.61M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 72.81M | 280.19M | 213.07M | 166.65M | 142.84M | 115.30M |
| Total Equity | -54.68M | -88.85M | 232.11M | 160.08M | 120.22M | 87.52M | 63.94M |
| Cash & Equivalents | - | 61.51M | 260.69M | 185.00M | 138.13M | 120.36M | 91.97M |
| Long Term Debt | - | 31.95M | 32.66M | 33.31M | 31.71M | 39.36M | 40.30M |
| Total Liabilities | - | 44.32M | 48.08M | 53.00M | 46.44M | 55.32M | 51.36M |
| Current Liabilities | - | 9.31M | 13.50M | 17.82M | 12.25M | 15.47M | 11.03M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -32.17M | -52.54M | -75.97M | -47.18M | -22.35M | -29.69M |
| Investing Cash Flow | -953.00K | -813.00K | -970.00K | -791.00K | -385.00K | -224.00K |
| Financing Cash Flow | 73.40M | 252.53M | 1.25M | 1.10M | 4.96M | 1.79M |
| Capital Expenditure | -953.00K | -813.00K | -970.00K | -791.00K | -385.00K | -224.00K |
| Free Cash Flow | -33.13M | -53.35M | -76.94M | -47.98M | -22.74M | -29.92M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | 66.7% | 82.4% | 82.7% | 85.3% | 85.5% | 86.2% |
| Operating Margin % | -116.5% | -105.2% | -117.7% | -70.7% | -63.3% | -48.0% |
| Net Margin % | -125.5% | -128.6% | -120.9% | -68.5% | -64.5% | -49.7% |
| ROE % | 39.0% | -27.1% | -53.9% | -46.2% | -58.8% | -60.1% |
| ROCE % | -50.7% | -19.3% | -43.0% | -37.1% | -39.7% | -35.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Long Focus Capital Management, LLC | 6.98% | 3.84M | $32.87M |
| 2 | Blackrock Inc. | 5.60% | 3.08M | $26.36M |
| 3 | Americana Partners, LLC | 3.05% | 1.68M | $14.36M |
| 4 | Pathstone Holdings, LLC | 3.05% | 1.68M | $14.36M |
| 5 | Vanguard Capital Management LLC | 2.86% | 1.57M | $13.46M |
| 6 | B Group, Inc. | 1.76% | 970.00K | $8.29M |
| 7 | Geode Capital Management, LLC | 1.74% | 958.57K | $8.20M |
| 8 | State Street Corporation | 1.52% | 835.45K | $7.14M |
| 9 | Acadian Asset Management. LLC | 1.46% | 806.58K | $6.90M |
| 10 | AQR Capital Management, LLC | 0.72% | 397.56K | $3.40M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SGHT
Sight Sciences (SGHT) Stock Sees Modest Fair Value Cut As Analysts Revisit Guidance - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxPeDVndVVfanlsV1I2V3UtUHpQWlgweGZtOGpMSlFOX280V0lJWDk2bVktcnlmeFlCd0c3RkVrMnpIM096ZDhUYWMxaHB5U2o1bHJkbkZJdXVUOXBuRmJkMmV6V1VDWEdOcWt3RFNQTHF0MnJNbDctczZ0Y3U2R3g5MkN2bEFIMVpmYTJVNH…
Former Sight Sciences (SGHT) officer lines up more stock sales - Stock Titan
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxQdllBd0ZsYXhrRFB5ZXVROWY4ZWdFdFpSWDhnMGQ0QkRoaC1xX205V3B4cUhPZTJSSlE4TVZhdUJEZUk3bXBLMVFLOVowN1dOZU9RRWlGY2Y3R1lCWi1ZcjFZaUgwdWJ1STd1UnJWU0hkYjBVQVNqaUplWUxxT296a1hyVEVmcnBBVEZUOW…
Sight Sciences Inc. (SGHT) Stock Falls on Q4 2025 Earnings - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxOcXhUM3Vldkc5YTZGRkYzaDRWdmY4ZXR5RVVIODZoWGJpTng5a0o4N3lfa0k4eUQzU3RLWXVSUFVMQnEwYVFxMmhpbVVTTWpLR1ZQYUdyLWFpTS1DUGRzdzlxM2h3NlduYnctc195b29jQWZGQktfMVIwMG9KYThSbVdrOGtzTkRRYVJPYm…
Price to sales forward of Sight Sciences, Inc. – NASDAQ:SGHT - TradingView
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxNU2RmeWJYNkJCU1QyblVic1ZSemlneFBwOUlRWERjNDY0Y1RuMWpCVUk2QTBYMFdnQjlyRzNfdUJFbkVTczBDd3Q4ZVM3anpMdWxfcERtZjBVVDhsbmZ5T25kUWZsQnF2bE92NVFTTXQ3THlJc1o1ZzZydGdpWFBWRHBMbGdFRnFGb29Ebl…
Morgan Stanley healthcare talk featuring Sight Sciences will stream live Sept. 15 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxPb280S2VkRjBIbVNnbXZSS0dJMFFxU2xBRUdTemJIOUFHbjFIc0I4dUp5MF9fM1pkbGNzUXh0ZUhHT1RodllqcjhOTmhnNE9NZDhtN3FrS05yWmdYMV9BbnE3SkpfMk1CYlN3bDF2SzhKSnppRS1va1R0amtIMTdJQVIwRFFQX2x5NmJZZj…
Have Insiders Sold Sight Sciences Shares Recently? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxNeWJWUjlBSy1VYXpaSnFpcU45V3BPMkw3UllTajh0emlpeDQ1aEI0Wk56SEVDTEEwMGZrQUxjdHZBUEV6NmlxTGRaVmpGQ2o5eWRKYWNZY2ZheURCWEdWUFpIZlpfaW83Y0pZWGlySkNwTVZMbjZtMTNhUnZhY2hyd0xLWmktTlFIWlEwWj…
SGHT — Frequently Asked Questions
What is the current share price of Sight Sciences, Inc. (SGHT)?
As of 2026-09-07 16:24 PDT, Sight Sciences, Inc. (SGHT) trades at $8.35 on NasdaqGS. Its 52-week range is $3.20 to $9.05.
What is the market capitalisation of SGHT?
Sight Sciences, Inc. (SGHT) has a market capitalisation of $459.98M on NasdaqGS.
What is the P/E ratio of SGHT?
SGHT trades at a trailing price-to-earnings (P/E) ratio of -15.18. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 7.72.
What is the return on equity (ROE) of SGHT?
SGHT has a return on equity (ROE) of -48.42%. Its return on capital employed (ROCE) is -35.58%.
Is SGHT a good stock to buy?
This page provides a data-driven analysis of Sight Sciences, Inc. (SGHT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.